A number of regimens have been explored for targeted 177Lu-treatment of colon carcinoma [26], various adenocarcinomas [27], ovarian carcinoma [28, 29], lung cancer [30], neuroendocrine tumors [31], HER-2 expressing tumors [32], and gastric cancer [33] among others. This evidence concerns the gene ERBB2 and adenocarcinoma.